文献速递眼底病与葡萄膜炎

钯-103敷贴放疗脉络膜黑色素瘤后第二和第三个十年的结局

The Second and Third Decade After 103Pd Plaque Brachytherapy for Choroidal Melanoma.
PubMed 文献 · Ophthalmology · 2026-10-14

这项回顾性队列研究纳入170例在纽约眼癌中心接受钯-103敷贴放疗的脉络膜黑色素瘤患者,随访至少10年。结果显示局部肿瘤控制率100%,仅1眼(0.6%)因新生血管性青光眼和患者选择而摘除;视力保留率(20/200或更好)在12年、15年、20年分别为92.7%、87.0%、63.7%。

要点

  • 局部肿瘤控制率达100%,眼球保留率高,仅0.6%摘除。
  • 视力保留率随时间下降:12年92.7%、15年87.0%、20年63.7%。
  • 肿瘤靠近黄斑者黄斑辐射剂量更高、视力更差;邻近视盘和环视盘肿瘤视力丧失率最高。

核心结论

  • 钯-103敷贴放疗脉络膜黑色素瘤在10年以上随访中局部控制率达100%,眼球保留率高,但长期视力保留率逐渐下降。
  • 肿瘤位置(靠近黄斑或视盘)与更差的视力结局相关,需在患者咨询和治疗决策中考虑。

研究设计与样本

  • 回顾性队列研究,纳入170例在纽约眼癌中心接受钯-103敷贴放疗的脉络膜黑色素瘤患者,随访至少10年。
  • 收集患者人口学特征、肿瘤大小、位置、AJCC临床T分类、视力结局、放疗后视网膜病变管理及长期眼部合并症数据。
  • 主要终点为肿瘤控制、眼球保留和视力;次要终点包括长期放疗相关并发症、额外眼部干预及相关合并症。
  • 统计分析采用Kaplan-Meier生存法、t检验、Wilcoxon秩和检验、卡方检验和线性回归图。

主要发现

  • 170例患者中局部肿瘤控制率100%,1眼(0.6%)因新生血管性青光眼和患者选择行眼球摘除。
  • Kaplan-Meier分析显示视力(20/200或更好)保留率:12年92.7%、15年87.0%、20年63.7%。
  • 放疗性视网膜病变采用抗血管内皮生长因子(anti-VEGF)治疗、玻璃体内皮质类固醇和激光治疗管理。
  • 肿瘤靠近黄斑与黄斑辐射剂量增加和更差视力结局相关;邻近视盘和环视盘肿瘤治疗与最高视力丧失率相关。

关键数值与推荐

  • 局部肿瘤控制率100%(170例,随访至少10年)。
  • 眼球摘除率0.6%(1眼,因新生血管性青光眼和患者选择)。
  • 视力(20/200或更好)保留率:12年92.7%、15年87.0%、20年63.7%。

临床怎么用

  • 钯-103敷贴放疗可提供优异的长期局部肿瘤控制和高眼球保留率,适用于脉络膜黑色素瘤。
  • 对靠近黄斑或视盘的肿瘤,应预期更高的视力丧失风险,需加强患者咨询和视力监测。
  • 放疗性视网膜病变可通过anti-VEGF、玻璃体内皮质类固醇和激光进行管理。

局限性

  • 回顾性队列研究设计,可能存在选择偏倚和信息偏倚。
  • 单中心研究,结果外推需谨慎。
  • 样本量170例,可能限制亚组分析的统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine long-term visual and ocular outcomes in a large cohort of patients with choroidal melanoma treated using palladium-103 (103Pd) plaque brachytherapy. DESIGN: This is a retrospective cohort study. PARTICIPANTS: 170 patients with a minimum of 10 years of continuous follow-up at The New York Eye Cancer Center following 103Pd plaque brachytherapy treatment for choroidal melanoma. METHODS: The study includes collected data consisting of patient demographic characteristics, tumor features, such as size, location, and AJCC clinical T-category (cT), visual outcomes, variables related to post-treatment retinopathy management, and long-term ocular comorbidities. MAIN OUTCOME MEASURES: The primary endpoints were tumor control, ocular conservation, and visual acuity. Secondary endpoints included long-term radiation-related complications, additional ocular interventions, and associated comorbidities. Statistical analyses were performed using the Kaplan-Meier survival method, t-tests, Wilcoxon rank-sum tests, chi-square tests, and linear regression plots. RESULTS: Among 170 patients with a minimum 10-year follow-up there was 100% local tumor control. One eye (0.6%) was enucleated due to neovascular glaucoma and patient choice. Kaplan-Meier analysis demonstrated visual acuity retention rates of 92.7% at 12 years, 87.0% at 15 years, and 63.7% at 20 years defined as vision of 20/200 or better. Radiation retinopathy was managed with anti-vascular endothelial growth factor (anti-VEGF) therapy, intravitreal corticosteroids, and laser treatment. Tumors located closer to the fovea were associated with increased foveal radiation doses and poorer visual acuity outcomes. Treatment of juxtapapillary and circumpapillary tumors was associated with the highest rates of vision loss. CONCLUSIONS: This study is the largest and longest follow-up analysis of 103Pd plaque brachytherapy for choroidal melanoma. It provides new long-term information on tumor control, ocular morbidity, and visual outcomes that are valuable for patient counseling and therapeutic decision-making.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Labkovich M, Finger PT. The Second and Third Decade After 103Pd Plaque Brachytherapy for Choroidal Melanoma. Ophthalmology. 2026. PMID: 42874810. doi:10.1016/j.ophtha.2026.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。